Abstract
The management of myeloma has largely changed since the introduction of immunomodatory drugs (iMIDs)and proteasome-inhibitors (PIs)in the last decade. Results on efficacy of different treatment result primarily from randomized controlled trials. Data on treatment effectiveness based on daily practice are sparse but necessary to provide complementary information. Within the available treatment options,choice seems to depend on frailty of the patient;primarily based on age, WHO-performance status and comorbidities.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
